Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

  • Rodríguez-Otero, P.
  • Mateos, M.V.
  • Martínez-López, J.
  • Hernández, M.T.
  • Ocio, E.M.
  • Rosiñol, L.
  • Martínez, R.
  • Teruel, A.I.
  • Gutiérrez, N.C.
  • Bargay, J.
  • Bengoechea, E.
  • González, Y.
  • de Oteyza, J.P.
  • Gironella, M.
  • Nuñez-Córdoba, J.M.
  • Encinas, C.
  • Martín, J.
  • Cabrera, C.
  • Palomera, L.
  • de Arriba, F.
  • Cedena, M.T.
  • Puig, N.
  • Oriol, A.
  • Paiva, B.
  • Bladé, J.
  • Lahuerta, J.J.
  • San Miguel, J.F.
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.